(NOV) Novo Nordisk - Overview
Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: XETRA (Germany) | Market Cap: 169.335m EUR | Total Return: 78.1% in 12m
Avg Turnover: 10.5M
EPS Trend: 93.7%
Rev. Trend: 96.9%
Qual. Beats: 1
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Novo Nordisk A/S is a Denmark-based pharmaceutical company specializing in chronic disease management, primarily through its Obesity and Diabetes Care and Rare Disease segments. The company develops and manufactures therapeutic products for diabetes, cardiovascular issues, rare blood disorders, and endocrine conditions, while also producing medical delivery devices such as smart insulin pens and injection needles.
The business model relies heavily on a vertically integrated supply chain and significant research and development investment to maintain a dominant share in the global insulin market. As part of the biotechnology sector, the company operates in a high-barrier industry characterized by stringent regulatory oversight and long-term patent protections for proprietary drug formulations.
To evaluate the long-term growth potential of these therapeutic segments, investors can examine the detailed financial metrics available on ValueRay.
Headquartered in Bagsvaerd, Novo Nordisk maintains an extensive global distribution network spanning North America, Europe, Asia, and emerging markets. Founded in 1923, the organization has evolved from a regional insulin producer into a multinational entity addressing large-scale public health challenges such as rising obesity rates.
- Wegovy and Ozempic demand accelerates global obesity and diabetes market share
- Manufacturing capacity expansion determines GLP-1 revenue trajectory and volume growth
- Medicare price negotiations and US regulatory scrutiny impact long-term net pricing
- Expansion into cardiovascular and kidney disease therapies diversifies pharmaceutical portfolio
- Competitive pressure from Eli Lilly affects pricing power and market leadership position
| Net Income: 122b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -4.86 > 1.0 |
| NWC/Revenue: -14.62% < 20% (prev -20.36%; Δ 5.74% < -1%) |
| CFO/TA 0.21 > 3% & CFO 119b > Net Income 122b |
| Net Debt (133b) to EBITDA (182b): 0.73 < 3 |
| Current Ratio: 0.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (4.45b) vs 12m ago 0.05% < -2% |
| Gross Margin: 81.85% > 18% (prev 0.84%; Δ 8.10k% > 0.5%) |
| Asset Turnover: 62.41% > 50% (prev 61.97%; Δ 0.43% > 0%) |
| Interest Coverage Ratio: 31.59 > 6 (EBITDA TTM 182b / Interest Expense TTM 5.08b) |
| A: -0.09 (Total Current Assets 177b - Total Current Liabilities 225b) / Total Assets 559b |
| B: 0.37 (Retained Earnings 206b / Total Assets 559b) |
| C: 0.31 (EBIT TTM 160b / Avg Total Assets 524b) |
| D: 0.57 (Book Value of Equity 203b / Total Liabilities 356b) |
| Altman-Z'' = 3.30 = A |
| DSRI: 1.08 (Receivables 100b/86.4b, Revenue 327b/303b) |
| GMI: 1.03 (GM 81.85% / 84.33%) |
| AQI: 0.99 (AQ_t 0.29 / AQ_t-1 0.29) |
| SGI: 1.08 (Revenue 327b / 303b) |
| TATA: 0.01 (NI 122b - CFO 119b) / TA 559b) |
| Beneish M = -2.88 (Cap -4..+1) = A |
As of May 24, 2026, the stock is trading at EUR 38.04 with a total of 280,090 shares traded.
Over the past week, the price has changed by +2.16%,
over one month by +2.92%,
over three months by +3.11% and
over the past year by +78.12%.
Novo Nordisk has no consensus analysts rating.
Market Cap DKK = 1265b (169b EUR * 7.4715 EUR.DKK)
P/E Trailing = 10.4087
P/E Forward = 13.3156
P/S = 0.5166
P/B = 6.2755
P/EG = 3.3057
Revenue TTM = 327b DKK
EBIT TTM = 160b DKK
EBITDA TTM = 182b DKK
Long Term Debt = 119b DKK (from longTermDebt, last quarter)
Short Term Debt = 27.2b DKK (from shortTermDebt, last quarter)
Debt = 155b DKK (from shortLongTermDebtTotal, last quarter) + Leases 8.57b
Net Debt = 133b DKK (calculated: Debt 155b - CCE 21.6b)
Enterprise Value = 1399b DKK (1265b + Debt 155b - CCE 21.6b)
Interest Coverage Ratio = 31.59 (Ebit TTM 160b / Interest Expense TTM 5.08b)
EV/FCF = 24.01x (Enterprise Value 1399b / FCF TTM 58.2b)
FCF Yield = 4.16% (FCF TTM 58.2b / Enterprise Value 1399b)
FCF Margin = 17.81% (FCF TTM 58.2b / Revenue TTM 327b)
Net Margin = 37.26% (Net Income TTM 122b / Revenue TTM 327b)
Gross Margin = 81.85% ((Revenue TTM 327b - Cost of Revenue TTM 59.4b) / Revenue TTM)
Gross Margin QoQ = 85.96% (prev 80.86%)
Tobins Q-Ratio = 2.50 (Enterprise Value 1399b / Total Assets 559b)
Interest Expense / Debt = 3.28% (Interest Expense 5.08b / Debt 155b)
Taxrate = 21.90% (13.6b / 62.2b)
NOPAT = 125b (EBIT 160b * (1 - 21.90%))
Current Ratio = 0.79 (Total Current Assets 177b / Total Current Liabilities 225b)
Debt / Equity = 0.76 (Debt 155b / totalStockholderEquity, last quarter 203b)
Debt / EBITDA = 0.73 (Net Debt 133b / EBITDA 182b)
Debt / FCF = 2.29 (Net Debt 133b / FCF TTM 58.2b)
Total Stockholder Equity = 184b (last 4 quarters mean from totalStockholderEquity)
RoA = 23.25% (Net Income 122b / Total Assets 559b)
RoE = 66.37% (Net Income TTM 122b / Total Stockholder Equity 184b)
RoCE = 52.99% (EBIT 160b / Capital Employed (Equity 184b + L.T.Debt 119b))
RoIC = 34.69% (NOPAT 125b / Invested Capital 361b)
WACC = 9.13% (E(1265b)/V(1420b) * Re(9.93%) + D(155b)/V(1420b) * Rd(3.28%) * (1-Tc(0.22)))
Discount Rate = 9.93% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -62.93 | Cagr: -0.29%
[DCF] Terminal Value 70.24% ; FCFF base≈64.8b ; Y1≈56.9b ; Y5≈45.9b
[DCF] Fair Price = 155.0 (EV 654b - Net Debt 133b = Equity 521b / Shares 3.36b; r=9.13% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 93.66 | EPS CAGR: 19.50% | SUE: N/A | # QB: 0
Revenue Correlation: 96.91 | Revenue CAGR: 19.16% | SUE: 4.0 | # QB: 1